GAIN THERAPEUTICS INC
GANXNASDAQTrading Snapshot
- Day Range
- $1.66 – $1.70
- 52-Week Range
- $1.53 – $4.34
- Volume
- $4.12B
- Avg Volume
- $5.01B
- Shares Outstanding
- 42.6M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $160,000
- Last Q Revenue
- $43,817
- P/E Ratio
- —
- P/S Ratio
- 482.8x
- EPS (TTM)
- $-0.51
- Dividend Yield
- —
- Dilution (1yr)
- +21.5%
Why Investors Own GANX
- ✓High-growth profile — revenue up +56.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GAIN THERAPEUTICS INC
GANX
StockOtter · stockotter.spaceAbout GAIN THERAPEUTICS INC
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of
Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison
Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the s
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of a
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of al
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of a
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26